Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc. (NASDAQ:ACTU) with a Buy rating and announced a price target of $20. Actuate Therapeutics shares closed at $7.98 on Monday. See how other analysts view this stock.
• HC Wainwright & Co. analyst Matthew Keller initiated coverage on Gyre Therapeutics, Inc. (NASDAQ:GYRE) with a Buy rating and announced a price target of $18. Gyre Therapeutics shares closed at $8.18 on Monday. See how other analysts view this stock.
• William Blair analyst Andrew Brackmann initiated coverage on CareDx, Inc (NASDAQ:CDNA) with a Market Perform rating. CareDx shares closed at $12.75 on Monday. See how other analysts view this stock.

Considering buying ACTU stock? Here’s what analysts think:

Read This Next:

• Top 3 Health Care Stocks You’ll Regret Missing This Quarter

Photo via Shutterstock